NASDAQ · VANI
Vivani Medical, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VANI: Nov 12, 2026
Vivani Medical, Inc. Common Stock (DE) is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.07. The reported EPS for the same quarter last year was $-0.11.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Dec 2026 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Mar 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Jun 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · MarketBeat · RTTNews · Zacks- The Motley Fool · Aug 29, 7:35 PM EDTHas Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?Novo Nordisk was first with a GLP-1 weight-loss shot, but lost the lead to Eli Lilly.
- MarketBeat · Jul 15, 7:02 PM EDTVivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk DealVivani Medical Surges on its Ozempic-Like Weight-Loss ImplantVivani Medical (NASDAQ:VANI) said it is preparing to begin human testing of its semaglutide implant in August and highlighted a recently announced agreement with Novo Nordisk to evaluate the company’s implant technology
- RTTNews · Jul 10, 12:10 PM EDTWeekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal(RTTNews) – This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech and pharmaceutical sectors.
- RTTNews · Jul 7, 9:16 AM EDTVivani Medical In Deal With Novo Nordisk To Evaluate Semaglutide Drug Implant NPM-139(RTTNews) – On Tuesday, Vivani Medical, Inc. (VANI), a biopharmaceutical company focused on ultra long-acting drug implants, announced a new agreement, under which Novo Nordisk B A/S (NVO) will evaluate its semaglutide drug implant NPM-139 for chronic weight management.
- Zacks · Apr 3, 12:00 PM EDTVivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Fintel · Mar 27, 3:03 AM EDTVivani Medical (VANI) Price Target Increased by 10.00% to 5.61The average one-year price target for Vivani Medical (NasdaqCM:VANI) has been revised to $5.61 / share. This is an increase of 10.00% from the prior estimate of $5.10 dated February 21, 2026. The price target is an average of many targets provided by analysts.
- RTTNews · Jan 26, 2:40 AM ESTVivani Prices Common Stock Offering At $1.48/Shr(RTTNews) – Vivani Medical, Inc. (VANI), a clinical-stage biopharmaceutical company, has offered to sell 1.69 million shares of common stock at $1.48 per share in a registered direct offering, along with a concurrent private placement of 1.35 million common shares at the same pri
- RTTNews · Jan 23, 1:54 AM ESTVivani Subsidiary Cortigent To Present Advanced Orion Brain-Implant Technology At NANS 2026, Today(RTTNews) – Vivani Medical Inc.'s (VANI) wholly owned subsidiary, Cortigent, is set to present new technical insights into its Orion Visual Cortical Prosthesis System, today, January 23, 2026, at the North American Neuromodulation Society annual meeting in Las Vegas. The investig
- Fintel · Dec 21, 11:42 AM ESTVivani Medical (VANI) Price Target Increased by 25.00% to 5.10The average one-year price target for Vivani Medical (NasdaqCM:VANI) has been revised to $5.10 / share. This is an increase of 25.00% from the prior estimate of $4.08 dated December 3, 2025. The price target is an average of many targets provided by analysts.
- RTTNews · Oct 29, 1:03 AM EDTGNTA, BBIO, AMRN Jump After Hours: Key Biotech Catalysts Driving Stock Gains(RTTNews) – Several biotech and healthcare stocks posted notable gains in after-hours trading, driven by clinical updates, strategic deals, and regulatory milestones. Below is a quick rundown of the top movers and the catalysts behind their price action.
- RTTNews · Jun 11, 8:29 AM EDTVivani Medical Appoints Anthony Baldor To Succeed Brigid Makes As CFO(RTTNews) – Vivani Medical, Inc. (VANI), a clinical-stage biopharmaceutical company, announced Wednesday the appointment of Anthony Baldor as Chief Financial Officer.
- Zacks · Jun 2, 8:38 AM EDTVivani Stock Gains After Announcing Spin-Off Plans for Cortigent UnitVANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Vivani Medical, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.